T1	Task 0 33	Mice bearing the orthotopic model
T2	Task 91 128	mice with the pseudo-metastatic model
T3	Process 231 247	test the effects
T4	Material 251 276	our targeted formulations
T5	Task 186 213	These therapeutic schedules
T6	Material 324 342	preclinical models
T7	Task 378 385	Animals
T8	Material 433 443	untargeted
T9	Material 457 481	peptide-targeted SL[DXR]
T10	Material 616 637	HEPES-buffered saline
T11	Task 492 534	Scrambled peptide-functionalized liposomes
T12	Material 639 653	Survival times
T13	Task 690 720	determining treatment efficacy
T14	Material 747 781	time-dependent anti-tumor activity
T15	Task 729 745	orthotopic model
T16	Material 1163 1174	d-luciferin
T17	Task 872 893	the GI-LI-N cell line
T18	Process 898 906	infected
T19	Process 1051 1061	visualized
T20	Task 994 1013	luciferase activity
T21	Material 1017 1046	retrovirally-transduced cells
T22	Material 445 452	SL[DXR]
R1	Hyponym-of Arg1:T22 Arg2:T8	
